RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.27
+1.64%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.02
- Revenue estimate
- $150.0K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- $0.46
- EPS estimate
- -$0.88
- Revenue actual
- —
- Revenue estimate
- $179.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -13.5%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $41
- PT range
- $38 – $44
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026